The bill amends Sections 27-18-90, 27-19-82, and 27-20-78 of the General Laws to require health insurance coverage for the treatment of pediatric autoimmune neuropsychiatric disorders linked to streptococcal infections and pediatric acute onset neuropsychiatric syndrome. This coverage is mandated for all group health insurance contracts and policies issued or renewed in the state starting January 1, 2023. Notably, the bill updates the terminology by replacing "immunoglobin" with "immunoglobulin" and removes the previous requirement for these disorders to be coded as autoimmune encephalitis for billing purposes until a specific code was established by relevant authorities.

Additionally, the bill eliminates the sunset provision that would have repealed the mandated coverage on December 31, 2025, ensuring that the coverage remains in effect indefinitely. It also removes the requirement for health insurance carriers to report on the costs and savings associated with this coverage, thereby simplifying the implementation process. The bill clarifies that coverage for these treatments must be provided both within and outside of Rhode Island, subject to a pre-authorization process if in-state services are unavailable. Overall, the amendments aim to improve access to essential medical treatments for affected children without previous limitations.